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Efficacy of different doses of ketamine as a bolus  
in major depressive disorder 
 
 
Abstract 
Background: Major depressive disorder is a severe, heterogeneous, common medical 
illness and a leading cause of disability throughout the world that poses a significant public 
health issue. Previous studies have shown rapid antidepressant effects following a single 
administration of ketamine. This study aimed to assess the impact of route of 
administration and dose of ketamine for the reduction of depressive symptoms and 
compare the effects of different doses and methods. 
Methods: A double-blind clinical controlled trial was done on 100 patients with a primary 
diagnosis of major depressive disorder who were assigned into two groups of 50 subjects 
at a dose of 0.5 mg/kg and 0.75 mg/kg ketamine and each group was divided into two 
groups of 25 subjects following a single dose of intravenous bolus and infusion of 
ketamine. The patient’s severity of depression was evaluated with Hamillton Depression 
Rating Scale and Beck Depression Inventory scores after 2 days, 7 days, 30 days and 60 
days of ketamine administration, then the results were compared between groups. 
Results: According to Hamilton and Beck score, the treatment response in investigated 
patients was 64% and 60%, respectively. 
Conclusions: These data suggest that ketamine effect is related to drug dose and type of 
administration. The dose of 0.75 mg/kg of ketamine is more effective than 0.5 mg/kg and a 
bolus injection of low-dose ketamine (0.5 mg/kg) is more effective than infusion and in 
high-dose ketamine (0.75 mg/kg), there was no difference between the methods of drug 
administration. 
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Major depressive disorder (MDD) is a severe, heterogeneous, common medical 
illness and a leading cause of disability throughout the world (1). With its high prevalence, 
disability, morbidity and mortality, depression poses a significant public health issue (2-4). 
Recently, the glutamate system has emerged as a critical focus of novel therapeutic 
development for depressive disorder and particularly treatment-resistant depression (5, 6). 
Yet, only half of individuals with major depressive episodes respond to the traditional 
antidepressants, that full clinical benefit of these is only achieved following weeks to 
months of treatment (7, 8). Therefore, with the challenges of existing pharmacotherapies, 
there is a clear and urgent need for rapid acting antidepressants with robust efficacy in 
patients especially who are refractory to traditional antidepressants (9). Ketamine, a 
noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist and FDA-approved 
anesthetic, is the prototype for a new generation of glutamate-based antidepressants that 
rapidly alleviate depression within hours of treatment (1). These rapid and potent 
antidepressant effects were also demonstrated in patient groups known to respond poorly 
to current antidepressants (10, 11).  
 Caspian J Intern Med 2018; 9(3):220-227  
Different doses of ketamine in major depressive disorder                      221 
Researchers found that low (subanesthetic) doses of this 
drug administered intravenously began to reduce depression 
symptoms within 4 h of administration in patients with 
severe treatment-resistant depression (12). This finding has 
since been replicated in multiple-controlled studies by 
several research groups (13, 14). Studies reported rapid 
antidepressant effects following a single administration of 
various routes and doses of ketamine, including 0.2 mg/kg 
intravenous bolus (15), 50 mg intranasal (16), 0.5 mg/kg or 
0.25 mg/kg intramuscular injection (17) and 0.5 mg/kg of 
ketamine intravenously infused over 40 min (18). NMDA 
receptor functions vary according to their subunit 
composition and subcellular location. Convergent evidence 
shows opposing effects of synaptic and extra synaptic 
NMDA receptors. Synaptic NMDA receptors promote 
synaptic formation and neuronal survival. In contrast, extra 
synaptic NMDA receptor activation promotes synaptic 
atrophy and neuronal death by altering nuclear calcium. This 
deregulates target gene expression, leading to mitochondrial 
dysfunction, reduced dendritic length and arborization, and 
synaptic loss (1).  
The actions of ketamine are unique. Ketamine is the first 
step in a cascade of events that includes rapid increases in 
presynaptic glutamate release, enhanced regional activity in 
excitatory networks, and ultimately marked changes in 
synaptic plasticity and connectivity (19-21). Given the 
known role of BDNF in the pathophysiology and treatment 
of depression, large trial did find a positive relationship 
between ketamine effects and peripheral BDNF levels and a 
polymorphism of the BDNF gene (1). Four hours post 
ketamine infusion, a significant increase in plasma BDNF 
was observed in responders compared to non-responders 
(22-25). Recent studies have concluded that single dosage 
regimen of intravenous, oral, intranasal and intramuscular 
ketamine were useful for treating unipolar and bipolar 
depression (16, 17). Several recent meta-analyses have also 
shown ketamine to be effective in managing depressive 
symptoms (13, 14, 26-28).  
We designed the present study to test the rapid 
antidepressant efficacy of ketamine in a relatively large 
group of subjects with treatment-resistant major depression. 
This study aimed to assess the impact of route of 
administration and dose of ketamine for the reduction of 
depressive symptoms and compares the effects of different 
doses and methods. We hypothesized that 0.75 mg/kg 
ketamine and bolus method would be superior to 0.5 mg/kg 
ketamine and infusion method in improving depressive 
symptoms 24 hours following a single injection. 
 
 
Methods 
The study enrolled patients at one academic site in Babol, 
Iran, (Yahyanejad Hospital), between January 2014 and 
September 2015. Patients were eligible to participate if they 
were 20 to 60 years of age, had a primary diagnosis of major 
depressive disorder as assessed with the Structured Clinical 
Interview for DSM-5 patient edition (29). 
Additional study inclusion criteria included a history of 
at least one major depressive episode according to DSM-5 
criteria with different severity and without psychotic feature 
and over the last month are not under medical treatment.  
Patients were excluded if they had a lifetime history of a 
psychotic illness, bipolar disorder, somatoform disorder or 
personality disorder, alcohol or substance abuse in the 
previous 2 years, medical illness such as hypertension and 
heart disease, serious and imminent suicidal behavior or 
homicidal risk, or a score less than 27 on the Mini-Mental 
State Examination (29) or if they were taking contraindicated 
medications. Each patient had a physical examination, 
routine hematologic and biochemical tests, urine toxicology 
measurements, and an electrocardiogram (ECG) to detect 
unstable medical illness or substance use. After complete 
description of the study to the subjects, written informed 
consent was obtained. 
The study patients were free of concomitant 
antidepressants and other psychotropic medication for the 
duration of the study and were drug-free prior to the 
injection, for at least 4 weeks. In this study, 100 patients with 
major depressive disorder included 50 women with an 
average age of years 45.82±10.02 (50%) and 50 men with an 
average age of 35.38±10.19 years (50%), every other one 
was randomly selected and assigned into two groups of 50 
subjects at a ketamine hydrocholoride (ROTEXMEDCA, 
GERMANY) dose of  0.5mg /kg and 0.75mg/kg and each 
group was divided into two groups of 25 subjects following a 
single dose of  intravenous bolus and infusion of  ketamine 
infused over 20 minutes.  
Following admission to a clinical research unit and an 
indwelling catheter was placed in the antecubital vein of the 
non-dominant arm, and pulse, blood pressure and ECG 
monitoring were instituted. Patients were discharged from 
the research unit 4 hours after the injection and were 
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clinically interviewed by a clinical psychologist, 48 hours, 7 
days, 30 days and 60 days post injection. Non-responders 
were considered patients with less than 50% improvement 
from baseline in the score on the Hamillton Depression 
Rating Scale (HDRS) (30) and Beck Depression Inventory 
scores (BDI) (31). As directed by the protocol, we stopped 
following the nonresponders 48 hours after the injection. 
Responders were followed until relapse or for an additional 
60 days, whichever came sooner. 
Data using statistical software SPSS 17 and a test of the 
model X 2, ANOVA, Fishers and logistic regression were 
analyzed. Crude and adjusted odd ratios were presented at 
95% confidence level. All statistical tests used a threshold of 
p≤0.05 for significance. 
The method for determining the sample size: 
 
 
(Z1-/2 ) =1.96 
(Z 1-)=0.84                       
P1 = Improvement in 0.75mg/kg group  
P2 = Improvement in 0.5mg/kg group 
Sample size was estimated at 95% confidence level and 
80% strength, with an assumption of recovery in group 0.75 
mg 85% and recovery in 0.5 mg group with 50% sample size 
for each group of 25 specimens. 
This study was registered by Iranian Registry of Clinical 
Trials (IRCT2015030921072N2). The study was approved 
by the Ethics Committee of Babol University of Medical 
Sciences on the nineteenth of March, 2015 (license number 
5262). 
 
 
Results  
Patients were eligible to participate if they were 20 to 60 
years of age (average age of 40.6±11.34 years), had a 
primary diagnosis of major depressive disorder. 
Since the response to treatment with ketamine reduced 
50% or more of the Hamilton and Beck test scores in 
patients considered based on the results of the test scores 
observed in all patients Hamilton noted that based on testing, 
64% and 60% of patients respond to treatment, Beck said. 
Also, fifty patients who underwent injections of 0.5 mg/kg of 
ketamine were given the Hamilton test results in 24 (48%) 
patients and according to the Beck test results, 22 (44%) 
responded to treatment. Fifty patients who underwent 
injection of 0.75 mg / kg of ketamine were given the 
Hamilton test results of 40 (80%) patients and while 38 
(76%) patients according to the Beck test results. So, a dose 
of 0.75 mg/kg is more effective than 0.5 mg/kg. In a dose of 
0.75 mg/kg, there is no difference between the route of 
injection and at a dose of 0.5 mg/kg, bolus method is 
effective respond to treatment (tables 1, 2). 
In this study, fifty-three patients aged forty years or less 
and forty-seven patients more than forty years old and 35 
patients of the 53 patients and 29 patients out of 47 patients 
responded to treatment, according to Hamilton test. Of the 
64 patients, 34 (53.1% were responding to treatment) 
females and 30 (46.9% were responding to treatment) males 
responded to treatment and no significant relationship was 
observed between age, gender, and response to treatment 
(p<0.05). 
 In this study, Hamilton patients test scores had 30 as 
severe major depressive disorder and from the 100 patients, 
58 subjects in this group had a 51.6% response to treatment, 
while the remaining 48.4% of 42 patients had responded to 
treatment, therefore, patients with severe major depression 
have lower response to ketamine (fig 1). 
Ketamine positive response to the first two days was 64% 
and 63% of the first week (one relapse) and 59% (five 
relapses) of the first month respectively. 25 patients did not 
return for follow-up in the second month and of the 39 
patients, 33 patients still retained a positive response. 
 
Table 1: Baseline characteristics of studied population 
P value Infusion 0.75mg 
n= 25 
Bolus 0.75mg 
n= 25 
Infusion 0.5mg 
n=25 
Bolus 0.5mg 
n=25 
 
 
0.437 
 
10 (40%) 
15 (60%) 
 
14 (56%) 
11 (44%) 
 
11 (44%) 
14 (56%) 
 
15 (60%) 
10 (40%) 
Sex 
       Male (%) 
       Female (%)      
0.658 39.72±10.18 42.84±12.17 39 ±11.49 40.84±11.75 Age (mean ± SD) 
0.730 33.52±7.6 35.32±10.04 33.16±9.27 32.64±8.27 Baseline Hamilton test scores (mean ± SD) 
0.901 34.44±9.42 36.04±11.56 33.76±11.87 34.84±10.56 Baseline Beck test scores (mean ± SD) 
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Table 2: Prevalence and frequency of treatment response based on Beck and Hamilton, according to the dosage and 
injection of ketamine 
 
Total R.B¹ Total R.H¹ Group 
²R(+) ²R(-) ²R(+) ²R(-) 
25 
100% 
25% 
15 
60% 
25% 
10 
40% 
25% 
25 
100% 
25% 
17 
68% 
26.6% 
8 
32% 
22.2% 
Bolus 0.5mg             Count 
%within Group 
%within Response 
25 
100% 
25% 
7 
28% 
11.7% 
18 
72% 
45% 
25 
100% 
25% 
7 
28% 
10.9% 
18 
72% 
50% 
Infusion 0.5mg         Count 
%within Group 
%within Response 
25 
100% 
25% 
19 
76% 
31.7% 
6 
24% 
15% 
25 
100% 
25% 
20 
80% 
31% 
5 
20% 
13.9% 
Bolus 0.75mg           Count 
%within Group 
%within Response 
25 
100% 
25% 
19 
76% 
31.7% 
6 
24% 
15% 
25 
100% 
25% 
20 
80% 
31% 
5 
20% 
13.9% 
Infusion 0.75mg       Count 
%within Group 
%within Response 
100 
100% 
100% 
60 
60% 
100% 
40 
40% 
100% 
100 
100% 
100% 
64 
64% 
100% 
36 
36% 
100% 
Total                         Count 
%within Group 
%within Response 
¹: reduction of fifty percent and more in the Beck test scores (R.B) and Hamilton test scores (R.H) 
²: Positive Response (+), negative Response (-) 
 
                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Comparison of the effects of ketamine with respect to dose and injection method in depression varying intensities 
 
Discussion 
These data suggest that ketamine effect is related to drug 
dose and type of administration. The dose of 0.75 mg/kg of 
ketamine is more effective than 0.5 mg/kg and a bolus 
injection of low-dose ketamine (0.5 mg/kg) is more effective 
than infusion and in high-dose ketamine (0.75 mg/kg), there 
was no difference between methods of drug administration. 
We were aware of prior evidence implicating N-methyl-D-
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aspartate (NMDA) receptors in the pathophysiology and 
treatment of depression (32, 33), ketamine is a 
noncompetitive N-methyl-D-aspartate (NMDA) glutamate 
receptor antagonist. The antidepressant effects emerged so 
rapidly following the administration of a single ketamine 
dose and persisted for so long (12). The antidepressant 
effects tend to emerge 1–2 h after the acute perceptual 
disturbances of ketamine have abated and can persist for two 
weeks or longer in some patients (34). In this study, the 
antidepressant effects of ketamine persisted 64% for two 
days, 63% for one week and 59% for one month. It is not 
clear what percentage of the NMDA receptor for 
antidepressant effects of ketamine  dose should be taken and  
what dose of ketamine can achieve it (35). More specifically, 
a series of recent studies in rodents has demonstrated that 
low-dose ketamine administration rapidly triggers three 
consecutive events: first, a presynaptic disinhibition of 
glutamatergic neurons, which leads to a glutamate surge; 
second, an increased activation of the AMPA glutamate 
receptor, combined with the blockade of extrasynaptic 
NMDA receptors; and third, a postsynaptic activation of 
neuroplasticity-related signaling pathways involving BDNF 
and mTORC1,which results in overall synaptogenesis and 
synaptic potentiation (19-21). Among other postsynaptic 
signaling pathways (36), the ketamine-induced 
synaptogenesis involves the inhibition of the eukaryotic 
elongation factor 2 (eEF2) kinase, leading to reduced eEF2 
phosphorylation and subsequently increased BDNF 
translation (37).  
In anesthetic doses of ketamine, there are no increases 
and may be even decreases in extracellular glutamate and in 
glutamate cycling (38, 39). Of interest, synaptogenesis and 
the antidepressant effects of ketamine are also limited to 
subanesthetic doses (20). Hence, there is a dose-response 
parallel between the glutamate surge, synaptogenesis, and 
the antidepressant effects of ketamine. In this study, 0.75 
mg/kg of ketamine was more effective than 0.5 mg/kg of 
ketamine may be because a greater percentage of NMDA 
receptors occupancy in high doses or presynaptic 
disinhibition of glutamatergic neurons, with increased 
activation of the AMPA glutamate receptor, combined with 
the blockade of extrasynaptic NMDA receptors; and 
postsynaptic activation of neuroplasticity-related signaling 
pathways involving BDNF and mTORC1, at higher doses. 
On the other hand, closer the anesthetic dose of ketamine, 
antidepressant effect can be reduced or even reversed, so 
more research is needed to find the right and more effective 
dose of ketamine. PET studies are recommended for this 
purpose.  
The latter is of particular relevance to clinical depression, 
which is associated with reduced prefrontal synaptic 
connectivity. A major form of homeostatic plasticity is 
“synaptic scaling,” which regulates the overall strength of 
neuronal synaptic connectivity. For example, a prolonged 
increase in neuronal activities produces a downscaling in 
overall synaptic strength (40). Among many other 
mechanisms (41), synaptic scaling is regulated by 
inflammatory cytokines (e.g., tumor necrosis factor) (42) and 
by neurotrophins [e.g., brain-derived neurotrophic factor 
(BDNF)], alteration in both factors has been associated with 
depression (43, 44). These synaptic changes are believed to 
result from stress-induced altered glutamate release and 
astroglial loss leading to neurotrophic factor deficits and 
sustain increase in extracellular glutamate. The excess 
glutamate precipitates excitotoxicity, altered synaptic 
strength, reduced dendritic spine density, dendritic 
retraction, and reduced dendritic branching in the PFC (45, 
46). Identifying signaling pathways implicated in the 
observed stress-related synaptic dysfunction it has been 
found that synaptic deficits are precipitated by the reduction 
in neurotrophic factors such as BDNF (44) and by inhibition 
of the mammalian target of rapamycin complex 1 
(mTORC1) signaling pathway (47). Enhancing mTORC1 
signaling or increasing BDNF produces antidepressant 
effects (44, 47). Together these data posit that enhancement 
of BDNF and mTORC1 signaling lead to prefrontal synaptic 
formation (synaptogenesis), and reversal of stress- and 
depression-induced neuronal atrophy and synaptic 
dysconnectivity are required for efficacious antidepressant 
treatment.  
In this study, ketamine’s response on depression with 
higher intensity (Hamilton score >=30) is weaker than lower 
intensity that was described above is justified. A bolus 
injection of low-dose ketamine (0.5 mg/kg) is more effective 
than infusion and probably for this reason ketamine bolus 
method is faster than infusion crossing the blood-brain 
barrier and reaches a dose optimum. In high-dose ketamine 
(0.75 mg/kg), there was no difference between methods 
probably due to dose 0.75 mg/kg which is closer to optimum 
dose and may be masking effect of injection method. 
Therefore, it seems that ketamine could theoretically play 
an important role in the treatment of severe and life-
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threatening disorders, particularly depression that requires 
immediate intervention, such as the use of ECT. The dose of 
0.75 mg / kg dose was more effective than 0.5 mg / kg and is 
closer to the proper dosage and in the low dose, during bolus 
injection drug passes faster than infusion from the blood 
brain barrier and reaches an appropriate level of treatment. 
The present study has shown that ketamine can quickly 
create appropriate therapeutic effect and even to maintain its 
therapeutic effect for about a month but given that, the 
duration of ketamine gradually decline towards the end of 
the second month, and since depression is an episodic 
disease, this is another reason to start antidepressant 
treatment after injection of ketamine because there is a 
possibility of recurrence in the future. As a result, the 
combination therapy involves the use of ketamine due to its 
rapid effects associated with conventional maintenance 
treatments as new therapeutic protocols recommended to 
improve symptoms of severe depression.  
The limitations of the study are as follows: a) the small 
number of patients who met the requirements to participate 
in the study. b) Patient's unwillingness to cooperate with 
ketamine experimental treatment. c) Failure to timely refer 
patients for tests to determine the severity of depression. 
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